Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2007

View Archived Issues

HDL mimetic CSL-111 shown to reduce atherosclerotic burden in the ERASE trial

Valortim demonstrates therapeutic effect in new primate model of anthrax

Plant-derived vaccine adjuvant shows enhanced immune response against hepatitis B in mice

Avanir provides business update

Phase II study of incyclinide in acne studies 40 mg dose

PRX-00023 studied in new phase IIb trial for major depressive disorder

FDA requires additional phase III study for cintredekin besudotox

Phase I/II data for Baxter's adjuvant-free pandemic H5N1 influenza vaccine

Hollis-Eden files IND to begin clinical testing of HE-3286 for metabolic disorders

European orphan drug status for Elafin

Udenafil demonstrates efficacy in erectile dysfunction phase IIb study

Structure and biological evaluation of CKD-501 presented at the ACS meeting

Novel glucocorticoid receptor modulator profiled at Merck

Provenge recommended for approval for prostate cancer

New data presented for bifeprunox

CanBas and Takeda collaborate in cancer

Aska licenses rights to JCR's recombinant FSH

PC-190708: a novel DNA gyrase B inhibitor identified at Prolysis

New agents for treating extrapyramidal disorders disclosed in recent Kissei patents

Recent patents report novel therapeutic agents for metabolic disorders

Recent Pfizer patent discloses new treatments for attention deficit hyperactivity disorder

Ceprotin approved for severe congenital protein C deficiency

Novartis suspends U.S. sales of Zelnorm

Janumet receives FDA approval

Lapatinib filed for approval in Japan for advanced breast cancer

Abbott seeks U.S. and E.U. approval of Humira for chronic plaque psoriasis

Twinrix approved for new accelerated dosing schedule

Exjade filed in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 11, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...